deltatrials

Hereditary angioedema (hae) Trials in Scottsdale, United States

Conditions / Hereditary angioedema (hae) / Scottsdale, United States

Hereditary angioedema (hae) is a medical condition with active clinical research programs worldwide.

12 total trials for this combination

Showing top 10 of 12 trials

Trials

NCT ID Title Status Phase
NCT02741596 Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE COMPLETED PHASE3
NCT00457015 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) COMPLETED PHASE3
NCT06842823 A Study of Navenibart in Participants With Hereditary Angioedema RECRUITING PHASE3
NCT00456508 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) COMPLETED PHASE3
NCT03845400 A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America COMPLETED
NCT01756157 Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks COMPLETED PHASE2
NCT02584959 Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema COMPLETED PHASE3
NCT05396105 Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema ENROLLING_BY_INVITATION PHASE2/PHASE3
NCT04583007 Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults NO_LONGER_AVAILABLE
NCT02586805 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE COMPLETED PHASE3

Related Pages